文献速递高血压血脂与心血管预防

降压药副作用药物基因组学分析:神经降压素通路与CYP3A4*22

Side effects in hypertension treatment: a pharmacogenomic analysis.
PubMed 文献 · Eur Heart J · 2026-08-03

该研究利用芬兰、英国和爱沙尼亚三个队列超过40万有基因分型的降压药使用者的纵向用药数据,将一年内用药轨迹分为继续、换药和停药,并对五类降压药进行全基因组关联分析。结果发现ACEI换药与神经降压素-NTSR1通路相关,dCCB换药与CYP3A4*22功能等位基因相关,多基因风险评分可预测ACEI咳嗽风险。

要点

  • NTSR1 G301R变异与ACEI换药风险降低及咳嗽风险降低相关。
  • CYP3A4*22等位基因与dCCB换药风险升高相关,或可指导基因型处方。
  • ACEI换药多基因风险评分前10%者咳嗽风险约为中间20%者的两倍。

核心结论

  • 研究结果将ACEI所致咳嗽的缓激肽假说扩展至神经降压素-NTSR1信号通路,并确定CYP3A4*22为dCCB换药的新型功能预测因子。
  • 用药轨迹可作为药物遗传学发现的框架。

研究设计与样本

  • 研究利用FinnGen、英国生物银行和爱沙尼亚生物银行三个队列中超过40万有基因分型的降压药使用者的纵向用药数据。
  • 将一年内短期降压药使用轨迹分为继续、换药或停药,并对五类降压药进行全基因组关联研究。

主要发现

  • 共鉴定出14个与从ACEI和dCCB换用其他降压药相关的全基因组显著位点。
  • ACEI换药证据集中于神经降压素-NTSR1通路,包括芬兰富集的NTSR1保护性错义变异rs148569146(G301R,OR 0.49,P=3.3×10-43)和RASSF9附近变异rs181941187(OR 0.74,P=1.2×10-49)。
  • 药物-基因交互分析中,NTSR1 G301R与ACEI诱导的咳嗽风险降低相关(OR 0.39,P=8.1×10-4)。
  • dCCB换药位点CYP3A43与功能等位基因CYP3A4*22(rs35599367)近乎完全连锁(r2=0.99,OR 1.23,P=6.1×10-10)。
  • 在爱沙尼亚生物银行独立样本中,ACEI换药多基因风险评分前10%者相比中间20%者,ACEI咳嗽风险约为两倍。

临床怎么用

  • NTSR1 G301R和CYP3A4*22等位基因可能有助于识别ACEI咳嗽或dCCB换药风险较高的患者,为基因型指导处方提供依据。
  • ACEI换药多基因风险评分可用于分层评估ACEI咳嗽风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Up to half of patients switch or discontinue antihypertensive medications within the first year, but underlying mechanisms remain elusive. This study aimed to identify genetic predictors of antihypertensive medication use trajectories within the first year. METHODS: Using longitudinal medication data from >400 000 genotyped antihypertensive medication users across three cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), short-term antihypertensive medication use trajectories were classified as Continue, Switch, or Discontinue. Genome-wide association studies were performed across five medication classes. RESULTS: In total, 14 genome-wide significant loci were identified for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, evidence converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], odds ratio [OR] 0.49, P = 3.3 × 10-43) and a variant near RASSF9 (rs181941187, OR = 0.74, P = 1.2 × 10-49) tagging the neurotensin gene NTS. In drug-gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR 0.39, P = 8.1 × 10-4). The dCCB switching locus at CYP3A43 was in near-complete linkage (r2 = 0.99) with the functional CYP3A4*22 allele (rs35599367, OR 1.23, P = 6.1 × 10-10). A polygenic risk score (PRS) for ACEI switching predicted two-fold ACEI cough risk in the top 10% PRS compared with the middle 20% in an independent sample of the Estonian Biobank. CONCLUSIONS: These findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signalling, pinpoint CYP3A4*22 as a novel functional predictor of dCCB switching with potential for genotype-guided prescribing, and validate medication use trajectories as a framework for pharmacogenetic discovery.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Vaura F, Krebs K, Kiiskinen T, et al. Side effects in hypertension treatment: a pharmacogenomic analysis. Eur Heart J. 2026. PMID: 42545033. doi:10.1093/eurheartj/ehag575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。